General, Soft tissue sarcomas, Other sarcoma diseases, Bone sarcomas, GIST (gastrointestinal stromal tumor)
Other clinical trials
HEROES-AYA will use bone and soft-tissue sarcomas caused by chimeric fusion genes as paradigmatic diseases to study the development of heterogeneity in human cancers with clonally dominant, truncal genetic drivers in multiple dimensions and translate the insights gained into new strategies for diagnostics, prognostication, prediction of treatment response and resistance, and, most importantly, therapeutic targeting of heterogeneous and continuously evolving tumors. Tumors will be subjected to novel analysis methods that allow deconvolution at single-cell and spatial resolution to capture tumor heterogeneity and evolution at multiple levels. This will be complemented by in vitro and in vivo validation of potential new vulnerabilities and the development of innovative clinical trials for well-defined patient cohorts across age groups with the clear aim of improving clinical outcomes based on the discoveries made in this project. HEROES-AYA aims to recruit 220 patients to study the following groups of disease: Ewing sarcoma, Alveolar rhabdomyosarcoma, Desmoplastic small round cell tumor, Alveolar soft part sarcoma, Synovial sarcoma, Inflammatory myofibroblastic tumor, NTRK-rearranged sarcomas, BCOR-rearranged sarcomas, CIC-rearranged sarcomas, Solitary fibrous tumor, Myxoid liposarcoma, Epithelioid hemangioendothelioma.
HEROES-AYA will use bone and soft-tissue sarcomas caused by chimeric fusion genes as paradigmatic diseases to study the development of heterogeneity in human cancers with clonally dominant, truncal genetic drivers in multiple dimensions and translate the insights gained into new strategies for diagnostics, prognostication, prediction of treatment response and resistance, and, most importantly, therapeutic targeting of heterogeneous and continuously evolving tumors. Tumors will be subjected to novel analysis methods that allow deconvolution at single-cell and spatial resolution to capture tumor heterogeneity and evolution at multiple levels. This will be complemented by in vitro and in vivo validation of potential new vulnerabilities and the development of innovative clinical trials for well-defined patient cohorts across age groups with the clear aim of improving clinical outcomes based on the discoveries made in this project. HEROES-AYA aims to recruit 220 patients to study the following groups of disease: Ewing sarcoma, Alveolar rhabdomyosarcoma, Desmoplastic small round cell tumor, Alveolar soft part sarcoma, Synovial sarcoma, Inflammatory myofibroblastic tumor, NTRK-rearranged sarcomas, BCOR-rearranged sarcomas, CIC-rearranged sarcomas, Solitary fibrous tumor, Myxoid liposarcoma, Epithelioid hemangioendothelioma.
